We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

80 hedge funds and large institutions have $142M invested in Synergy Pharmaceuticals, Inc Common Stock in 2014 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 35 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

119% more call options, than puts

Call options by funds: $1.55M | Put options by funds: $709K

11% more funds holding

Funds holding: 7280 (+8)

2% more capital invested

Capital invested by funds: $139M → $142M (+$3.05M)

11% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 35

Holders
80
Holders Change
+8
Holders Change %
+11.11%
% of All Funds
2.31%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
31
Reduced
35
Closed
6
Calls
$1.55M
Puts
$709K
Net Calls
+$844K
Net Calls Change
+$249K
Name Holding Trade Value Shares
Change
Change in
Stake
SM
26
Sabby Management
Florida
$718K +$2.12M +377,908 New
U
27
UBS
Switzerland
$716K +$509K +90,842 +206%
CS
28
Credit Suisse
Switzerland
$691K +$56.4K +10,055 +8%
TA
29
Teachers Advisors
New York
$635K +$22.4K +3,996 +3%
AllianceBernstein
30
AllianceBernstein
Tennessee
$627K +$160K +28,565 +32%
B
31
Bailard
California
$613K -$1.29M -229,767 -67%
Deutsche Bank
32
Deutsche Bank
Germany
$599K +$76.5K +13,649 +14%
AGM
33
Alpine Global Management
New York
$531K -$7.85K -1,400 -1%
SIP
34
Stoneridge Investment Partners
Pennsylvania
$525K -$25.4K -4,529 -4%
Millennium Management
35
Millennium Management
New York
$446K -$401K -71,530 -46%
Swiss National Bank
36
Swiss National Bank
Switzerland
$423K +$67.6K +12,066 +18%
ARC
37
Absolute Return Capital
Massachusetts
$412K +$435K +77,675 New
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$359K -$27.6K -4,921 -7%
MLICM
39
Metropolitan Life Insurance Company (MetLife)
New York
$358K -$5.29K -944 -1%
Goldman Sachs
40
Goldman Sachs
New York
$340K +$49.7K +8,874 +16%
NFA
41
Nationwide Fund Advisors
Ohio
$328K -$11.7K -2,085 -3%
VOYA Investment Management
42
VOYA Investment Management
Georgia
$328K -$4.84K -864 -1%
AIG
43
American International Group
New York
$311K -$19.9K -3,544 -6%
DekaBank Deutsche Girozentrale
44
DekaBank Deutsche Girozentrale
Germany
$292K +$15.6K +2,779 +5%
Wells Fargo
45
Wells Fargo
California
$287K +$300K +53,471 +10,547%
Bank of America
46
Bank of America
North Carolina
$279K +$39.2K +6,990 +15%
JP Morgan Chase
47
JP Morgan Chase
New York
$255K +$269K +48,026 New
Citigroup
48
Citigroup
New York
$225K -$123K -21,932 -34%
BA
49
BlackRock Advisors
Delaware
$223K +$7.05K +1,257 +3%
Citadel Advisors
50
Citadel Advisors
Florida
$206K +$217K +38,757 New

SGYP Hedge Fund Activity: Q1 2014 in Review

80 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q1 2014, worth a combined $142M — up 2.2% from $139M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new SGYP positions and 6 closed out — a net gain of 8 holders — while 31 added to existing stakes and 35 trimmed.

The largest buyer was State Street, adding an estimated $11.4M. The largest seller was Baker Bros. Advisors, cutting an estimated $4.97M.

  • 80 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q1 2014, up from 72 in Q4 2013.
  • Funds reported $142M of Synergy Pharmaceuticals, Inc Common Stock stock for Q1 2014, up 2.2% quarter-over-quarter.
  • 14 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q1 2014 and 6 closed out, a net change of +8 holders.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q1 2014 was State Street, an estimated $11.4M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q1 2014 was Baker Bros. Advisors, an estimated $4.97M sold.

Based on aggregated 13F filings for Q1 2014.